NovogeneAIT Genomics has been appointed as the service provider for the PRECISE-SG100K proteomics project in Singapore. The company will process and generate data from 10,000 plasma samples, a collaboration led by Thermo Fisher Scientific and PRECISE, aimed at supporting precision medicine research.
The project will employ Thermo Fisher Scientific’s Orbitrap Astral mass spectrometry platform, alongside Seer’s Proteograph Product Suite and Olink’s Reveal Assay, to conduct deep proteomic profiling. This initiative seeks to uncover novel biomarkers and biological signatures linked to ageing and disease through high-throughput analysis.
John Zhang, Senior Commercial Director of NovogeneAIT, remarked, “Being appointed as the service lab for this landmark study represents a major leap forward in our capability to support large-scale proteomics research in Singapore.” He emphasised the collaboration’s potential to deliver actionable insights and contribute to Singapore’s National Precision Medicine Programme.
Prof. John Chambers, Chief Scientific Officer at PRECISE, noted the partnership’s significance, stating, “This collaboration further strengthens the PRECISE-SG100K dataset, through addition of mass spectroscopy based assessment of proteomic variation.” He highlighted its role in enhancing understanding of disease mechanisms and supporting future translational research.
The completion of this 10,000 sample pilot study is anticipated to serve as a proof of concept, demonstrating the potential of large-scale proteomics in advancing medical research.
